Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.18 -5.2%	$2.70	$1.05 ▼ $4.13	$315.89M	1.89	596,737 shs	125,315 shs
HRMY Harmony Biosciences	$34.33 -1.1%	$33.59	$26.47 ▼ $41.61	$1.97B	0.83	631,807 shs	46,937 shs
HRTX Heron Therapeutics	$2.09 -1.7%	$2.04	$1.04 ▼ $3.73	$318.10M	1.18	2.15 million shs	166,194 shs
PRLD Prelude Therapeutics	$0.83 +1.3%	$0.89	$0.61 ▼ $6.80	$46.86M	1.22	289,161 shs	4,571 shs
SUPN Supernus Pharmaceuticals	$33.54 -1.3%	$32.26	$27.05 ▼ $40.28	$1.87B	0.7	486,328 shs	40,434 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+5.82%	+23.85%	-7.50%	+179.83%	-12.46%
HRMY Harmony Biosciences	+2.09%	+7.66%	+5.28%	+20.73%	+2.84%
HRTX Heron Therapeutics	-2.75%	-1.40%	+9.84%	+10.42%	-34.57%
PRLD Prelude Therapeutics	+0.65%	+1.65%	-14.59%	+9.00%	-82.02%
SUPN Supernus Pharmaceuticals	+2.54%	+7.98%	+6.03%	+7.95%	+18.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.5532 of 5 stars	3.5	1.0	0.0	1.3	0.8	0.6
HRMY Harmony Biosciences	4.858 of 5 stars	4.5	1.0	0.0	4.0	3.3	4.4
HRTX Heron Therapeutics	3.6773 of 5 stars	3.5	0.0	4.2	2.2	1.7	0.6
PRLD Prelude Therapeutics	3.7306 of 5 stars	3.5	5.0	0.0	2.7	3.3	0.6
SUPN Supernus Pharmaceuticals	1.5474 of 5 stars	1.2	1.0	4.1	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	144.09% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.33	49.53% Upside
HRTX Heron Therapeutics	3.00	Buy	$5.00	139.81% Upside
PRLD Prelude Therapeutics	3.00	Buy	$4.50	442.17% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	7.35% Upside

Current Analyst Ratings Breakdown

Latest HRTX, SUPN, PRLD, ADCT, and HRMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $55.00
7/10/2025	HRMY Harmony Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$33.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
5/5/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.45	N/A	N/A	($2.10) per share	-1.51
HRMY Harmony Biosciences	$714.73M	2.76	$2.97 per share	11.54	$11.56 per share	2.97
HRTX Heron Therapeutics	$148.52M	2.14	N/A	N/A	($0.22) per share	-9.48
PRLD Prelude Therapeutics	$7M	6.69	N/A	N/A	$2.39 per share	0.35
SUPN Supernus Pharmaceuticals	$661.82M	2.84	$4.22 per share	7.94	$18.76 per share	1.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	13.10	11.04	0.47	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
PRLD Prelude Therapeutics	-$127.17M	-$1.69	N/A	N/A	N/A	N/A	-89.18%	-69.26%	8/11/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.11	30.16	23.29	N/A	9.27%	12.23%	9.17%	8/5/2025 (Estimated)

Latest HRTX, SUPN, PRLD, ADCT, and HRMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	PRLD Prelude Therapeutics	-$0.45	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	N/A	N/A	N/A	$204.37 million	N/A
8/5/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	N/A	N/A	N/A	$38.08 million	N/A
8/5/2025	Q2 2025	SUPN Supernus Pharmaceuticals	$0.47	N/A	N/A	N/A	$154.06 million	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.47	-$0.42	+$0.05	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
HRMY Harmony Biosciences	0.22	3.67	3.63
HRTX Heron Therapeutics	N/A	2.40	1.76
PRLD Prelude Therapeutics	N/A	5.18	5.18
SUPN Supernus Pharmaceuticals	N/A	2.44	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
HRMY Harmony Biosciences	86.23%
HRTX Heron Therapeutics	80.01%
PRLD Prelude Therapeutics	79.72%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
HRMY Harmony Biosciences	23.60%
HRTX Heron Therapeutics	5.86%
PRLD Prelude Therapeutics	63.90%
SUPN Supernus Pharmaceuticals	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.38 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	51.06 million	Optionable

HRTX, SUPN, PRLD, ADCT, and HRMY Headlines

Recent News About These Companies

Principal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 15 at 3:26 AM | marketbeat.com

Rice Hall James & Associates LLC Sells 12,456 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 14 at 6:35 AM | marketbeat.com

Stephens Investment Management Group LLC Has $56.94 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 13 at 6:26 AM | marketbeat.com

Wall Street Zen Upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy

July 12 at 2:42 AM | marketbeat.com

2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution

July 10, 2025 | finance.yahoo.com

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)

July 9, 2025 | msn.com

Head-To-Head Analysis: Supernus Pharmaceuticals (NASDAQ:SUPN) & Personalis (NASDAQ:PSNL)

July 5, 2025 | americanbankingnews.com

Meritage Portfolio Management Acquires 10,622 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 4, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (SUPN) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

8,151 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Robeco Institutional Asset Management B.V.

July 3, 2025 | marketbeat.com

Sage Sacks Entire Staff After Supernus Buyout

June 30, 2025 | biospace.comB

Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions

June 27, 2025 | msn.com

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years

June 23, 2025 | uk.finance.yahoo.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street Zen

June 21, 2025 | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Supernus Pharma to Buy Sage Therapeutics for Up to $795 Million

June 16, 2025 | marketwatch.com

Supernus enters depression drug market with up to $795 million Sage deal

June 16, 2025 | msn.com

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

June 16, 2025 | msn.com

Supernus to acquire depression drugmaker Sage

June 16, 2025 | msn.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

June 16, 2025 | prnewswire.com

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal

June 16, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, SUPN, PRLD, ADCT, and HRMY Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.18 -0.18 (-5.22%)

As of 10:39 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Harmony Biosciences NASDAQ:HRMY

$34.33 -0.38 (-1.09%)

As of 10:40 AM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Heron Therapeutics NASDAQ:HRTX

$2.08 -0.04 (-1.65%)

As of 10:39 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Prelude Therapeutics NASDAQ:PRLD

$0.83 +0.01 (+1.34%)

As of 10:36 AM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Supernus Pharmaceuticals NASDAQ:SUPN

$33.53 -0.43 (-1.25%)

As of 10:39 AM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time